Live Pharma Statistics Webinar
Introduction and Software Implementation of Non-Proportional Hazards in Network Meta-Analysis: Fractional Polynomial and Piecewise Exponential Models
Looking to strengthen your HTA submissions with advanced statistical methods?
Join the European Federation of Statisticians in the Pharmaceutical Industry (EFSPI) Health Technology Assessment (HTA) European Special Interest Group (ESIG) for a deep dive into time-dependent network meta-analysis models. Petauri Evidence is delighted to host and facilitate this statistics webinar for the EFSPI and UK Statisticians in the Pharmaceutical Industry (PSI) HTA ESIG. This session will show you how to move beyond constant hazard ratio assumptions and implement fractional polynomial and piecewise exponential approaches in R.
In this session:
- Speaker: Anna Wiksten (Associate Director Biostatistics, Bristol Myers Squibb) will give a short presentation to introduce the topic
- Facilitator for Q&A: Ash Bullement (Director – HEOR, Petauri Evidence)
When: Tuesday 27th January, 13:00 GMT/14:00 CET
How to join: Register now to attend live or to receive the recording after the webinar
What will the webinar explore:
Standard network meta-analysis assumes a constant hazard ratio, which is sometimes inappropriate. Time‑dependent network meta-analysis methods are increasingly used in HTA but are often seen as methodologically challenging. This webinar introduces two time‑dependent network meta-analysis models – fractional polynomial and piecewise exponential – and summarises how they can be implemented in R.
Ask a question:
We invite you to put your questions to Anna during the session. Please suggest a question when you register.
Who should attend:
The webinar is free and open to all EFSPI and PSI members, as well as HEOR and market access professionals across the Pharmaceutical, Medtech, and Diagnostics industries.
More about our speaker:
Anna Wiksten (Associate Director Biostatistics, Bristol Myers Squibb)
Anna Wiksten (PhD) has worked on various drug development projects as a statistician and statistical programmer for the past 15 years. Beyond her current role as an Associate Director of Biostatistics at Bristol Myers Squibb, she is also the chairperson for Statisticians in the Finnish Pharmaceutical Industry (SSL), an EFSPI council member, and EFSPI President for 2026–2027. She has broad experience in regulatory submissions, indirect treatment comparisons, estimands, automatisation, and business development in a CRO. She is passionate about understanding the big picture in drug development and finding ways for statisticians to improve drug development processes through technical and people leadership skills.
Share